Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNPO9Q)

Drug Name

Uracil Drug Info

Synonyms

Xyfid; Uracil topical

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dihydrothymine dehydrogenase (DPYD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Eniluracil	DM96NCR	Hyperlipidaemia	5C80	Phase 2	[3]
RO-09-4889	DMQ65YW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
FL-386	DMUQN83	Hyperlipidaemia	5C80	Discontinued in Phase 2	[5]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[6]
5-Iodouracil	DM4O6I5	Discovery agent	N.A.	Investigative	[6]
(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione	DMA5DO2	Discovery agent	N.A.	Investigative	[6]
6-Carboxymethyluracil	DM9MPDK	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dihydrothymine dehydrogenase (DPYD)	TTZPS91	DPYD_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2	Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7.
3	Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49.
4	Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35.
5	Effects of FL-386 on faecal lipid excretion in humans. J Int Med Res. 1993 Sep-Oct;21(5):225-33.
6	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.